Valuation Metrics Reflect Enhanced Attractiveness
Lupin’s current P/E ratio stands at 19.01, a figure that positions it favourably against its pharmaceutical peers. For context, Zydus Lifesciences trades at a P/E of 20.48, while Mankind Pharma’s valuation is markedly higher at 50.93, signalling Lupin’s relative undervaluation. The company’s price-to-book value of 4.88 further reinforces this view, indicating a reasonable premium over book value compared to sector heavyweights such as Laurus Labs, which commands a P/BV multiple well above 9.
Enterprise value to EBITDA (EV/EBITDA) at 12.13 and EV to EBIT at 14.37 also suggest Lupin is trading at a discount relative to some peers, with Aurobindo Pharma’s EV/EBITDA at 12.89 and Biocon’s at 23.08. These valuation multiples, combined with a PEG ratio of 0.25, highlight the company’s strong earnings growth potential relative to its price, a key factor in the recent upgrade to a Strong Buy rating by MarketsMOJO on 1 July 2026.
Financial Performance and Returns Outpace Benchmarks
Beyond valuation, Lupin’s operational metrics are impressive. The company boasts a return on capital employed (ROCE) of 37.51% and a return on equity (ROE) of 25.68%, both indicative of efficient capital utilisation and strong profitability. These figures are well above industry averages, signalling Lupin’s ability to generate superior returns for shareholders.
In terms of stock performance, Lupin has delivered a remarkable 21.77% return over the past year, significantly outperforming the Sensex, which declined by 8.09% over the same period. The stock’s year-to-date return of 13.47% contrasts sharply with the Sensex’s negative 9.74%, while its three-year cumulative return of 165.48% dwarfs the benchmark’s 18.86%. This sustained outperformance underscores the market’s growing recognition of Lupin’s value proposition.
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
Comparative Valuation: Lupin vs. Peers
When analysing Lupin’s valuation in the context of its pharmaceutical peers, the company emerges as a compelling investment candidate. Zydus Lifesciences, with a P/E of 20.48 and PEG ratio of 1.27, appears fairly valued, while Mankind Pharma’s P/E of 50.93 and PEG of 34.1 suggest a stretched valuation. Laurus Labs and Biocon, despite commanding high valuations, have PEG ratios of 0.62 and 0 respectively, indicating varying growth expectations.
Lupin’s PEG ratio of 0.25 is particularly noteworthy, signalling that the stock’s price growth is not only supported by earnings growth but is also undervalued relative to that growth. This metric is a critical factor in the recent upgrade of Lupin’s Mojo Grade from Buy to Strong Buy, reflecting increased confidence in the company’s future earnings trajectory and valuation appeal.
Stock Price Movement and Market Capitalisation
Currently trading at ₹2,396.50, Lupin’s stock price has seen a slight dip of 0.98% on the day, closing just below its previous close of ₹2,420.15. The stock remains close to its 52-week high of ₹2,492.00, demonstrating resilience despite minor intraday fluctuations. The day’s trading range between ₹2,391.25 and ₹2,440.40 reflects moderate volatility within a generally bullish trend.
As a mid-cap company, Lupin’s market capitalisation and valuation metrics position it well for investors seeking growth with a balanced risk profile. The company’s dividend yield of 0.50% adds a modest income component, complementing its capital appreciation potential.
Curious about Lupin Ltd. from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Outlook and Investment Considerations
Lupin’s upgraded valuation grade to “very attractive” reflects a market reassessment of its growth prospects and risk profile. The company’s strong ROCE and ROE ratios, combined with a low PEG ratio, suggest that earnings growth is sustainable and not yet fully priced in by the market. This creates a favourable entry point for investors seeking exposure to the Pharmaceuticals & Biotechnology sector.
However, investors should remain mindful of sector-specific risks such as regulatory changes, pricing pressures, and competitive dynamics. Lupin’s ability to maintain its operational efficiency and capitalise on emerging market opportunities will be critical to sustaining its valuation premium.
In comparison to the broader market, Lupin’s stock has consistently outperformed the Sensex across multiple time horizons, including a 5-year return of 109.07% versus the Sensex’s 47.03%. This track record of outperformance, coupled with improved valuation metrics, supports the Strong Buy rating and suggests that Lupin remains a compelling pick for long-term investors.
Summary
Lupin Ltd.’s recent valuation shift from attractive to very attractive, supported by robust financial metrics and superior market returns, marks a pivotal moment for investors. The company’s P/E ratio of 19.01, PEG ratio of 0.25, and strong capital returns distinguish it from peers and underpin the upgrade to a Strong Buy rating. Trading near its 52-week high with a solid growth outlook, Lupin offers a balanced proposition of growth and value in the Pharmaceuticals & Biotechnology sector.
For investors seeking a fundamentally strong mid-cap stock with consistent growth and price strength, Lupin Ltd. stands out as a reliable choice in a competitive industry landscape.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
